Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.
Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.
Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.
The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.
From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.
Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.
Merck (NYSE: MRK) has announced that Caroline Litchfield, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on Monday, March 7, at 12:50 p.m. ET. This virtual event invites investors, analysts, media, and the public to listen via a provided link. With over 130 years in the industry, Merck continues to focus on developing medicines and vaccines to combat various diseases globally.
Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022, at 9:10 a.m. EST. A live video webcast of the event will be accessible for investors, analysts, media, and the public. Organon, a global healthcare company formed from a Merck spin-off, focuses on women's health with a diverse portfolio of over 60 products. The company aims to innovate and partner with biopharmaceutical innovators, leveraging its significant global presence.
Merck (NYSE: MRK) announced the retirement of Dr. Julie L. Gerberding, chief patient officer, effective May 2022. Dr. Gerberding will join the Foundation for the National Institutes of Health as CEO on May 16. During her 12-year tenure at Merck, she significantly enhanced the company's commitment to patient care and sustainability, contributing to its environmental, social, and governance strategies. CEO Robert M. Davis praised her leadership and impact on both the company and global health initiatives.
Organon (NYSE: OGN) has appointed Meghan Rivera as the new US Managing Director, bringing over 20 years of experience in biopharmaceuticals and digital therapeutics. Ms. Rivera will lead the company's US Commercial Operations team, consisting of 400 staff, aiming to capitalize on growth in women's health, biosimilars, and established brands. Previously, she held key roles at Akili Interactive and AMAG Pharmaceuticals. Organon, a company spun off from Merck (NYSE: MRK), has a strong portfolio of over 60 products focused on women's health, supported by solid cash flows for innovation and growth.
Merck (NYSE: MRK) and Eisai have received approval from Japan's Ministry of Health for the combination of KEYTRUDA, an anti-PD-1 therapy, and LENVIMA, a receptor tyrosine kinase inhibitor, for treating radically unresectable or metastatic renal cell carcinoma (RCC). This approval follows promising results from the CLEAR/KEYNOTE-581 trial, where the combination showed a 61% reduction in the risk of disease progression or death, with a median progression-free survival of 23.9 months compared to 9.2 months for sunitinib.
This is KEYTRUDA plus LENVIMA's second approval in Japan, previously approved for advanced endometrial carcinoma.
Merck (NYSE: MRK) is hosting a virtual Investor Event at
Organon reported 2021 revenue of $6.3 billion, a 3% decline from 2020, driven by losses in Established Brands. However, Nexplanon and biosimilars saw double-digit growth. Q4 revenue decreased by 1%, with a significant 46% drop in net income from continuing operations year-on-year. The company anticipates 2022 revenue between $6.1 billion and $6.4 billion, with adjusted EBITDA margins projected at 34%-36%. A quarterly dividend of $0.28 was declared, payable on March 17, 2022.
Organon (NYSE: OGN) has announced the acquisition of rights to Marvelon® and Mercilon® contraceptive pills from Bayer AG in China, Hong Kong, and Macau, with an additional agreement for Vietnam expected to close in H1 2022 pending regulatory approval. This acquisition expands Organon's contraceptive portfolio, providing opportunities to reach more women in these markets. Currently, Marvelon and Mercilon are available over the counter in China and Hong Kong, while they are prescription-based in Vietnam. This strategic move aligns with Organon’s goal to enhance women’s health offerings globally.
Merck (NYSE: MRK) has announced new leadership for its Human Health business, effective February 28, 2022. Arpa Garay will direct Global Marketing, while Jannie Oosthuizen will manage the U.S. operations. In the interim, Deepak Khanna will lead Human Health International. These changes aim to enhance operational effectiveness and build on the company's successes. CEO Robert M. Davis expressed confidence in the new structure, emphasizing the importance of internal talent development and focusing on business goals within the global health portfolio.
AstraZeneca and Merck (MRK) announced positive results from the Phase 3 PROpel trial, revealing that LYNPARZA combined with abiraterone plus prednisone significantly improves radiographic progression-free survival (rPFS) for metastatic castration-resistant prostate cancer (mCRPC) patients. The trial showed a 34% reduction in disease progression risk, with median rPFS at 24.8 months for LYNPARZA versus 16.6 months for the control. Although overall survival showed a trend towards improvement, it did not reach statistical significance. Adverse events primarily included anemia and fatigue.
FAQ
What is the current stock price of Merck & Co. (MRK)?
What is the market cap of Merck & Co. (MRK)?
What are the main therapeutic areas Merck focuses on?
What is Merck for Mothers?
What are some of Merck’s key products in oncology?
How significant is Merck’s vaccine business?
Where is Merck headquartered?
What percentage of Merck’s sales comes from the United States?
What is Merck's approach to research and development?
What recent achievements has Merck announced?
Does Merck collaborate with other companies for research?
What is the historical origin of Merck & Co., Inc.?
